OncoMatch/Clinical Trials/NCT06187597
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
Is NCT06187597 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including S-1 and Toripalimab for locally advanced esophageal squamous cell carcinoma.
Treatment: S-1 · Toripalimab — Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities. Previous trials have demonstrated that CRT with oral S-1 was tolerable and provided significant survival benefits over radiotherapy alone in elderly patients with esophageal squamous cell carcinoma (ESCC). However, as high as 54% of patients with elderly ESCC experienced locoregional or distant recurrence after CRT. Therefore, a more effective regimen for older patients is needed. Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown substantial clinical benefits in advanced esophageal cancer. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in locally advanced esophageal cancer. The aim of this study was to evaluate the efficacy and safety of toripalimab (an anti-PD-1 antibody) after concurrent CRT in elderly patients with locally advanced ESCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any anti-tumor therapy (chemotherapy, radiotherapy, surgery, immunotherapy)
Patients who have been treated previously with anti-tumor therapy (including chemotherapy, radiotherapy, surgery, immunotherapy, etc.)
Lab requirements
Blood counts
white blood cell count (wbc) ≥4.0×109/l, absolute neutrophil count (anc) ≥1.5×109/l; platelets ≥100×109/l; hemoglobin ≥9g/dl
Kidney function
serum creatinine ≤1.5×uln or creatinine clearance rate >60 ml/min
Liver function
total bilirubin ≤1.5×uln, alt, ast and/or akp ≤2.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify